Seres brings the microbiome back to life
Like many biotechs the group pushed on into phase III after a phase II failure; remarkably, the strategy has worked.
Microbiotica’s Roche deal sets up new microbiome test
A deal between the microbiome specialist Microbiotica and Roche’s Genentech division has raised hopes in the sector again.
Where is the IPO class of 2014-15 now?
A golden age for biotech flotations yielded some spectacular blow-ups, but also saw several groups reward investors with premium-priced takeovers.
